Drugs / PLUMBAGIN
PLUMBAGIN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04677855 | Mar 2021 → Oct 2023 | prostate cancer | Pellficure Pharmaceuticals, Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03137758 | Jul 2017 → Apr 2019 | prostate carcinoma | Pellficure Pharmaceuticals, Inc | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLUMBAGIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL295316 ↗ |
| Known as | NSC-236613 | ChEMBL registry synonym — accepted as the source's own label CHEMBL295316 ↗ |
| Known as | NSC-688284 | ChEMBL registry synonym — accepted as the source's own label CHEMBL295316 ↗ |
| Known as | PCUR-101 | “PCUR-101 Capsules 25 mg are solid dosage forms for oral administration” NCT03137758 ↗ |
| Modality | Small molecule | — CHEMBL295316 ↗ |
| Route | Oral | “oral administration” NCT03137758 ↗ |